← Eichor
Study identifier: NCT05850962 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock

Condition: Critical Illness · Shock  ·  Sponsor: Rakshit Panwar

PhaseNA
Planned participants1260
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP (mean arterial blood pressure) targets during vasopressor therapy for shock in ICU are individualized based on patients' own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings. Hypothesis We hypothesize that targeting a patient's pre-illness MAP during management of shock can minimize the degree of MAP-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU. Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality. Significance To date no major RCT has tested this strategy among ICU patients with shock. This pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care.

This description comes directly from the study's public registry record.

Talk to the study team

Rakshit Panwar, PhD, MD, FCICM, MBBS  ·  +61240420951  ·  rakshitpanwar@hotmail.com

Flonda Probert  ·  REACTSHOCKRCT@newcastle.edu.au

Always discuss trial participation with your own doctor first.

Locations (1)

Hunter Medical Research InstituteNewcastle, New South Wales, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05850962